The Future of Biotechnology Patents: How Judge Bryson’s Dissent in Association for Molecular Pathology v. Myriad Genetics, Inc. Raises Telling Questions
25 Pages Posted: 5 Sep 2012
Date Written: February 17, 2012
As technological advancements have grown exponentially over the years, the clarity of patent eligible subject matter standards has become murkier. This Comment seeks to delve into the ever-changing biotechnology industry and the potentially unforeseen effects that may result from the direction different courts are moving. The Comment will focus on a contested issue in the recently decided case Association for Molecular Pathology v. Myriad Genetics, Inc. – a decision containing various analyses of the composition claims of isolated DNA molecules.
Keywords: Intellectual Property, Biotechnology Patents
Suggested Citation: Suggested Citation